logo
Plus   Neg
Share
Email

Genentech : Late-stage Study Of Tecentriq On Advanced-stage Ovarian Cancer Fails To Meet PFS

Genentech, a member of the Roche Group (RHHBY), said that a late-stage IMagyn050 study showed that the addition of Tecentriq to Avastin, paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival or PFS for the front-line treatment of women with newly-diagnosed advanced-stage ovarian cancer.

But, the company said that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.

Data for the overall survival co-primary endpoint are currently immature and follow-up will continue until the next planned analysis, the company said.

Results from IMagyn050 will be further evaluated in order to inform the Tecentriq gynecological development program. The Tecentriq program in ovarian cancer and cervical cancers builds on the combination with Avastin, which has helped women with newly diagnosed, advanced or relapsed ovarian and cervical cancers live without their disease getting worse, as demonstrated in results across seven pivotal Phase III trials that involved more than 5,000 women.

Genentech noted that it has an extensive development program for Tecentriq, including multiple ongoing and planned Phase III studies across lung, genitourinary, skin, breast, gastrointestinal, gynecological, and head and neck cancers. This includes studies evaluating Tecentriq both alone and in combination with other medicines.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Securities and Exchange Commission is investigating the circumstances around Eastman Kodak Co.'s (KODK) announcement of a $765 million government loan to make ingredients for Covid-19 drugs, the Wall Street Journal reported citing people familiar with the matter. The National Retail Federation or NRF said that conflicting economic data amid a resurgence in coronavirus cases has made it difficult to predict how steadily the U.S. economic recovery will continue. NRF Chief Economist Jack Kleinhenz noted that based on quarterly and monthly data, the U.S. economic recovery is continuing despite the elevated COVID-19 cases. Ford Motor Company (F) announced that Jim Hackett plans to retire as President and CEO. He will continue as a special advisor to the company through March of 2021. The company has named Jim Farley as new president and CEO. He will join the board of directors, effective Oct. 1. Farley joined Ford in...
Follow RTT